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Abstract: We performed an overview of systematic reviews and meta-analyses to summarize available
data regarding the association between frailty and all-cause mortality. Medline, Embase, CINAHL,
Web of Science, PsycINFO, and AMED (Allied and Complementary Medicine) databases were
searched until February 2020 for meta-analyses examining the association between frailty and
all-cause mortality. The AMSTAR2 checklist was used to evaluate methodological quality. Frailty
exposure and the risk of all-cause mortality (hazard ratio [HR] or relative risk [RR]) were displayed
in forest plots. We included 25 meta-analyses that pooled data from between 3 and 20 studies.
The number of participants included in these meta-analyses ranged between <2000 and >500,000.
Overall, 56%, 32%, and 12% of studies were rated as of moderate, low, and critically low quality,
respectively. Frailty was associated with increased risk of all-cause mortality in 24/24 studies where
the HR/RRs ranged from 1.35 [95% confidence interval (CI) 1.05–1.74] (patients with diabetes) to
7.95 [95% CI 4.88–12.96] (hospitalized patients). The median HR/RR across different meta-analyses
was 1.98 (interquartile range 1.65–2.67). Pre-frailty was associated with a significantly increased
risk of all-cause mortality in 7/7 studies with the HR/RR ranging from 1.09 to 3.65 (median 1.51,
IQR 1.38–1.73). These data suggest that interventions to prevent frailty and pre-frailty are needed.
Keywords: frailty; mortality; evidence synthesis; meta-analyses; umbrella review
1. Introduction
Frailty, defined as a geriatric syndrome characterised by increased vulnerability to even minor
stressors and decreased physiological reserve [1,2], is common among older people. Globally,
it has been estimated that about 4.3% of older adults aged 60 years and older will develop frailty
per year [3]. However, the prevalence of frailty varies widely among older people: 4.0–59.1% in
community-dwelling older adults [4], 10.4–37.0% in general surgery patients [5], 6.0–86.0% in cancer
patients [6], and 19.0–75.6% in nursing home residents [7].
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Numerous studies have shown frailty to be associated with many negative health outcomes
including increased risk of hospitalizations [8], disability [9], falls [10], fractures [11], delirium [12],
and institutionalization [13]. Owing to these adverse effects, frailty is associated with higher healthcare
use and cost burden [14–16].
Moreover, frailty has been associated with increased risk of mortality and premature death [1,17,18],
and this effect has been suggested to be stable across different generational cohorts [19]. In particular,
Shamliyan and colleagues have suggested that 3–5% of deaths among community-dwelling adults could
be averted if there are concerted efforts to prevent frailty [20]. The exact mechanisms underpinning
increased mortality among people who are frail remains unclear, although, there are suggestions that
reduced physical and cognitive functions associated with frailty leads to poor prognosis [21,22]. Others
have also indicated that it is the underlying clinical conditions associated with frailty that are ultimately
the cause of death [23,24]. For example, an underlying physical or even psychological condition can
give rise to weight loss, which contributes to the development of frailty [25]. Whether or not the effects
of frailty on mortality risk are ubiquitous or more profound in selected subgroups is also unclear.
Thus, this umbrella review summarizes evidence generated from systematic reviews and
meta-analyses that examined the association between frailty and all-cause mortality across different
population groups and settings.
2. Methods
This review was performed according to the recommendations outlined in the Meta-analysis of
Observational Studies in Epidemiology [26], the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statements [27] (Supplementary Table S1), and the Cochrane Collaboration
Handbook [28].
2.1. Search Strategy and Study Selection
A systematic literature search of Medline, Embase, CINAHL, Web of Science, PsycINFO, and AMED
(allied and complementary medicine) databases for systematic reviews and meta-analyses examining
the association between frailty and the risk of all-cause mortality. The search was first performed in
August 2019 and was last updated in February 2020. The main keywords used included “frailty OR
frailty syndrome OR frail elderly OR geriatric syndrome OR geriatric disorder” AND “systematic
review OR meta-analysis OR review”. The full search strategy is presented in Supplementary Table S2.
In addition, the reference lists of included systematic reviews and meta-analyses were manually
screened. The literature search was independently performed by two reviewers (RO and KLC),
and disagreements were resolved by consensus involving a third author (BWS).
2.2. Selection Criteria
The inclusion criteria were as follows: (1) participants: any population; (2) study design:
meta-analyses that reported pooled risk estimates (hazard ratios [HRs] or risk ratios [RRs]; (3) exposure:
frailty or pre-frailty as defined by any criteria; and (4) outcome: risk of all-cause mortality. We restricted
the review to only studies reporting HRs and RRs as these are measures are largely comparable, and in
other reviews have been pooled together [28]. The exclusion criteria were as follows: (1) studies
published in languages other than English; (2) meta-analyses that did not follow the methodology
of a systematic review; (3) meta-analyses that pooled frailty scores without categorisation; and (4)
systematic reviews without meta-analysis.
2.3. Data Extraction
Two researchers (KLC and BWS) independently extracted the following data from the original
studies using a standardized data collection form: (1) author identification and year of publication;
(2) databases searched for systematic review; (3) search date; (4) number of studies included; (5) age
of the participants; (6) length of follow-up; (7) number of frail and non-frail populations; (8) frailty
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assessment tool used; (9) reported risk estimates; (8) heterogeneity reported; and (9) AMSTAR2 risk
of bias rating [29]. We also extracted age- or sex-specific risk estimates if reported. Where studies
reported effect of frailty at different follow-up periods, we prioritized the data on long-term mortality
effects. Disagreements in data collection were resolved by discussion involving a third author (RO).
2.4. Quality Assessment
Two investigators (BS and KLC) independently assessed the methodological quality of each study
after concealment of information about the authors, affiliations, date and source. A standardized
checklist, the AMSTAR2 appraisal tool, for reporting systematic reviews and meta-analyses was
used [29]. This checklist includes 16 criteria, each referring to a relevant methodological aspect of
the study. For each review, we applied a rating of high, moderate, low, or critically low for the
overall confidence in the results. The ratings were performed by two reviewers (BS and KLC) and any
disagreements were resolved via consensus involving third reviewer (RO).
2.5. Data Synthesis
To depict the relationship between frailty and all-cause mortality, the risk estimates (HR/RR)
and corresponding 95% confidence intervals (CIs) for each meta-analysis were displayed in a forest
plot [30–32]. Using the point HR/RR from each study, we also calculated the median risk estimate
along with corresponding interquartile range (IQR) to describe the distribution of the reported effect of
frailty on all-cause mortality. The level of heterogeneity across individual meta-analysis was assessed
via the I2 statistic, and depending on its values heterogeneity was considered as the following: might
not be important (0–40%), may represent moderate heterogeneity (30–60%), substantial heterogeneity
(50–90%), or considerable heterogeneity (75–100%) [28]. Forest plots were produced using StataSE
software version 16 (StataCorp, TX, USA), which displayed data from original meta-analyses without
including any additional analyses.
3. Results
3.1. Characteristics of Included Studies
Our search identified 4930 citations. A total of 150 articles were selected for full text examination
while others were removed following initial screening based on titles and abstract or duplicates. Of the
150 articles, 24 were eligible for analysis. One additional study was retrieved via reference screening.
The studies’ selection process is summarised in Figure 1.
The descriptive characteristics of the included studies are presented in Table 1. The meta-analyses
were published between 2015 and 2019 and included between three and 24 studies with sample sizes
ranging from <2000 to >500,000 participants. All the systematic reviews and meta-analyses conducted
their search in two or more databases. The meta-analyses focused on community-dwelling older adults
(n = 3); patients who had undergone transcatheter aortic valve implantation or replacement (n = 3),
percutaneous coronary intervention (PCI; n = 1), or left ventricular assist device implantation (n = 1);
vascular surgery patients (n = 1); patients with chronic kidney disease or end-stage renal disease
(n = 1); patients with heart failure (n = 4), diabetes (n = 1), acute coronary syndrome (ACS; n = 3),
or multiple myeloma (n = 1); patients who had been admitted to an intensive care unit (ICU; n = 1),
nursing home residents (n = 1); patients who had undergone a range of other surgical interventions
(n = 3) or those hospitalized for a range of medical conditions (n = 1).
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Table 1. Descriptive characteristics of the included meta-analyses.
Author Databases Searched SearchPeriod
No. of
Studies
Pooled
Population/Setting Age %Women
Countries of
Included Studies
Follow
up
Duration
Total
Sample
(%
Frail)
Exposures
Assessed
Pre-Defined
Frailty
Measurement
Criteria
Frailty
Mortality
HR/RRs
(95% CI)
Model
used I
2
AMSTAR
Quality
Rating
Anand et al.
[33]
Medline, Embase
and Cinahl
1 January
2000 to 1
June 2015
7 TAVI patients Mean age:81–86 y 48–66%
Switzerland,
Canada, Germany,
Netherlands,
Italy, USA
>30 days 3159(23.2%) Frailty Any
1.63
(1.34–1.97) a RE 66.0% Moderate
Huang et al.
[34]
PubMed, Embase and
Cochrane library
Inception
to
January
2018
10 TAVR patients NR NR
USA, Poland,
Germany, Spain,
Japan, Switzerland
>6
months
2992
(32.5%) Frailty Any
2.81
(1.90–4.15) b RE 84.0% Moderate
Ida et al. [35] Medline, Cochrane centraland Clinicaltrials.gov
Inception
to 1
December
2018
4 (Frail
vs.
non-frail)
2
(pre-frail
vs.
non-frail)
Patients with
diabetes
Mean age:
56–76 y 46–67%
Italy, USA, Spain,
Taiwan 3–12 y
563,761
(NR)
Frailty,
Pre-frailty Any
Frailty: 1.35
(1.05–1.74) a
Pre-frailty:
1.09
(1.01–1.17) a
RE
92.0%
(Frailty)
89.0%
(Pre-
frailty)
Moderate
Kojima et al.
[36]
Embase, Scopus, Medline,
Cinahl PsycINFO and
Google scholar
Inception
to March
2018
3
Community-
dwelling
middle-aged
and older
adults
Mean age:
≥59.9 y 0–53.4%
UK, Mexico, Italy,
Belgium,
Denmark, France,
Greece, Italy,
Netherlands,
Spain, Sweden,
Switzerland
2.4–4.3 y 9273(NR)
Frailty,
Pre-frailty FRAIL scale
Frailty: 3.53
(1.66–7.49) a**
Pre-frailty:
1.75
(1.14–2.70) a
RE
79.0%
(Frailty)
64.0%
(Pre-
frailty)
Moderate
Man et al.
[37] PubMed and Embase
Inception
to
October 1
2018
5 (Frailty)
3
(Pre-frailty)
Patients with
ACS ≥65 y 32.8–48.9
Canada, Spain,
France, Sweden
≥12
months
1270
(38.4%)
Frailty,
Pre-frailty Any
Frailty: 2.44
(1.92–3.12) a
Pre-frailty:1.65
(1.01–2.69) a
FE
0.0%
(Frailty),
0.0%
(pre-
frailty)
Critically low
Muscedere
et al. [38]
Cochrane central,
Medline, Embase,
PubMed, Cinahl and
Clinicaltrials.gov
Inception
to April
2017
6
Patients
admitted to the
ICU
Mean age:
57.1–84.0 y NR
USA, Canada,
Turkey, France
>6
months
2484
(42.8%) Frailty Any
1.53
(1.40–1.68) b RE 0.0% Moderate
Panayi et al.
[39]
PubMed and
Cochrane central
Inception
to 1
January
2018
11
Surgical
patients (All
surgeries)
NR NR USA, Canada NR 523,598(70.7%) Frailty
Modified
frailty index
(mFI)
4.19
(2.96–5.12) b RE 91.0% Moderate
Salazar et al.
[40]
Medline, Embase, Scopus,
Cochrane Database of
Systematic Reviews,
Cochrane Central, and
Clinicaltrials.gov
Inception
to
August
2018
3
Patients with
multiple
myeloma
Median
age: 58–74 NR
Italy, Czech
Republic,
Netherlands,
China, Germany
13–28
months
1622
(NR) Frailty Any
2.17
(1.00–2.34) a RE 33.7% Critically low
Sandini et al.
[41]
Medline, Embase,
PubMed, Cochrane and
Scopus libraries
1990 to
January
2017
8
Elective major
abdominal
surgery
patients
NR NR
USA, Korea,
Norway,
Netherlands
Up to 1 y 16,825(NR) Frailty Any
2.71
(1.63–4.49) a RE 88.3% Moderate
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Table 1. Cont.
Author Databases Searched SearchPeriod
No. of
Studies
Pooled
Population/Setting Age %Women
Countries of
Included Studies
Follow
up
Duration
Total
Sample
(%
Frail)
Exposures
Assessed
Pre-Defined
Frailty
Measurement
Criteria
Frailty
Mortality
HR/RRs (95%
CI)
Model
used I
2
AMSTAR
Quality
Rating
Shu-Fang
et al. [42]
Medline and CINAHL
databases and the
Cochrane Library
January
2001 to
July 2014
11
Community-
dwelling older
adults
≥65 y NR
France, Spain,
USA, Israel,
Finland
1.5–10 y 35538(NR)
Frailty,
Pre-frailty
Fried (CHS)
criteria
Frailty:2.00
(1.73–2.32) a
Pre-frailty:
1.34
(1.26–1.41) a
RE
61.7%
(Frailty)
0.0%
(Pre-
frailty)
Moderate
Thongprayoon
et al. [43]
Medline, Embase, the
Cochrane Central Register
of Controlled Trials, and
the Cochrane Database of
Systematic Reviews
Inception
to
November
2016
8 TAVR patients NR NR USA, Germany,France NR
10,498
(NR) Frailty Any
2.01
(1.44–2.80) b RE 58.0% Moderate
Tse et al. [44] PubMed and EMBASE
Inception
to July
23 2017
8
Patients who
have
undergone PCI
Mean age
69 y 32
Spain, Indonesia,
UK, Japan, USA
Mean
2.5 y
2332
(NR) Frailty Any
2.97
(1.56–5.66) a RE 79.0% Low
Tse et al. [45] PubMed and Embase
Inception
to
September
11, 2017
7
Advanced
Heart Failure
Patients
Undergoing
Left
Ventricular
Assist Device
Implantation
Mean age
48–69 y 20.8
Mean 13
months
2942
(13.5%) Frailty Any
1.44
(1.15–1.80) a FE 0.0% Moderate
Vermeiren
et al. [46]
PubMed, Web of
Knowledge and
PsycINFO
Inception
to
January
2016
17
Community-
dwelling older
adults
≥65 y NR
USA, France,
Spain, Cuba,
Dominican
Republic,
Venezuela, Mexico,
Peru, India, China,
Italy, Finland
10–120
months
150,763
(NR) Frailty Any
1.83
(1.68–1.98) a/b n.s 98.0% Low
Wang et al.
[47]
Medline, Embase,
Cochrane, Scopus
Inception
to
September
2017
9
Patients who
have
undergone
major vascular
surgery
Mean age
≥59.1 y NR
Canada, USA,
Japan 1–8.4 y
1957
(35.5%) Frailty Any
2.22
(1.81–2.73) a RE 0.0% Moderate
Wang et al.
[48]
PubMed, Embase,
Cochrane, Web of science
Inception
to
November
8 2017
6 Patients withheart failure
Mean age:
82.6 y 17.6 USA, Italy, Spain >30 days
1747
(53.0%) Frailty Any
1.70
(1.41–2.04) a FE 0.0% Low
Yang et al.
[49]
Medline, Embase,
Cochrane Central
January
1966 to
March
2018
8
Patients with
chronic heart
failure
Mean age:
73.4 y 40.1
USA, Italy,
Australia, Spain NR
2645
(50.7%) Frailty Any
1.54
(1.34–1.75) a RE 0.0% Moderate
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Table 1. Cont.
Author Databases Searched SearchPeriod
No. of
Studies
Pooled
Population/Setting Age %Women
Countries of
Included Studies
Follow
up
Duration
Total
Sample
(%
Frail)
Exposures
Assessed
Pre-Defined
Frailty
Measurement
Criteria
Frailty
Mortality
HR/RRs (95%
CI)
Model
used I
2
AMSTAR
Quality
Rating
Zhang et al.
[50]
Medline, Embase,
Cochrane Central
Inception
to
October
2018
14 Nursing homeresidents
Mean
age:84.9 72.1
France, Spain,
Canada, Belgium,
USA, Japan,
Poland, China,
Australia
0.5–9 y 9076(53.9%) Frailty Any
1.88
(1.57–2.25) a RE 47.8% Moderate
Zhang et al.
[51]
Medline, Embase,
Cochrane Central
Inception
to
October
2018
3 Heart failurepatients NR NR USA, Spain NR NR Frailty Any
Pre-frailty: 1.51
(0.99–2.31) a RE 0.0% Critically low
Zhang et al.
[52] PubMed and Embase
Inception
to
December
3 2017
20 Patients withheart failure
Mean age:
79.9 y 11.1–60.9
USA, Spain, Italy,
Australia, Canada,
UK, Hong Kong
0.5–12 y 17201(9.2–76%) Frailty Any
1.59
(1.39–1.82) a RE 55.0% Low
Dou et al.
[53] PubMed and Embase
Inception
to July
1 2018
7 Patients withACS ≥65 y NR
Spain, France,
Sweden, Canada,
Japan, South
Africa,
Scandinavia, India,
East Asia,
Australia, New
Zealand
In
hospital
to 56.4
months
6658
(12.3%) Frailty Any
Frailty: 2.65
(1.81–3.89) a
Pre-frailty: 1.41
(1.19–1.66) a
RE
60.2%
(Frailty)
0.0%
(Pre-
frailty)
Low
Zhang et al.
[54]
PubMed, Web of Science,
Embase and Cochrane
Central databases
Inception
to June
2019
11
Patients with
CKD or
end-stage renal
disease
Mean age:
>45.0 y
USA, South Korea,
India 1–17 y
127037
(7.9–82.0%) Frailty Fried (CHS)
1.95
(1.50–2.53) a RE 82.0% Low
Houghton
et al. [55]
Cinahl, PsycInfo,
and Scopus
inception
to
September,
2018
9
Vascular
surgery
patients
NR USA, Japan, UK NR 2904 Frailty Any 1.85(1.31–2.62) a RE 74.0% Low
Cunha et al.
[56]
PubMed, Embase, Web of
Science, Lilacs, Cinahl,
PsycInfo and Google
Scholar
Inception
to March
2019
4
(Frailty);
3
(Pre-frailty)
Hospitalized
patients NR NR
7–12
months
2119
(86.6%)
Frailty,
Pre-frailty Any
Frailty: 7.95
(4.88–12.96) a,
Pre-frailty:
3.65
(1.41–9.43) a
RE
0.0%
(Frailty),
28.0%
(pre-
frailty)
Moderate
Zhang et al.
[57]
Medline, Embase, and
Cochrane Central
Inception
to
December
2018
Patients with
ACS NR NR
15–60
Months
4665
(12.8%) Frailty Any
1.66
(1.35–2.05) a FE 11.0% Low
a = hazard ratio, b = risk ratio, HF = heart failure, ACS = acute coronary syndrome, CI = confidence interval, CKD = chronic kidney disease, FE = fixed effect model, ICU = intensive care
unit; n.s. = not stated, RE = random effect model, TAVI = transcatheter aortic valve implantation patients; TAVR = transcatheter aortic valve replacement, LVAD = left ventricular assist
device implantation;** in this study the reference group was only robust people.
Geriatrics 2020, 5, 17 7 of 14
Geriatrics 2020, 5, x 2 of 21 
 
Figure 1. Flow chart of studies’ selection process. 
The descriptive characteristics of the included studies are presented in Table 1. The meta-
analyses were published between 2015 and 2019 and included between three and 24 studies with 
sample sizes ranging from <2000 to >500,000 participants. All the systematic reviews and meta-
analyses conducted their search in two or more databases. The meta-analyses focused on community-
dwelling older adults (n = 3); patients who had undergone transcatheter aortic valve implantation or 
replacement (n = 3), percutaneous coronary intervention (PCI; n = 1), or left ventricular assist device 
implantation (n = 1); vascular surgery patients (n = 1); patients with chronic kidney disease or end-
stage renal disease (n = 1); patients with heart failure (n = 4), diabetes (n = 1), acute coronary syndrome 
(ACS; n = 3), or multiple myeloma (n = 1); patients who had been admitted to an intensive care unit 
(ICU; n = 1), nursing home residents (n = 1); patients who had undergone a range of other surgical 
interventions (n = 3) or those hospitalized for a range of medical conditions (n = 1). 
Figure 1. Flow chart of studies’ selection process.
The heterogeneity (I2) across the individual meta-analyses was variable and ranged from 0% to
100%. Fifty-six percent (14/25) of studies reported substantial to a considerable level of heterogeneity.
In the studies which reported frailty prevalence, the baseline prevalence of frailty ranged fro 7.9%
to 86.6%.
After evaluation of the risk of bias by the AMSTAR 2 tool, 56% (14/25), 32% (8/25), and 12% (3/25)
were rated to be of moderate, low, and critically low quality, respectively. The critical do ains that
ere most frequently lacking were justification for exclusion of individual studies (22 out of 25), lack
of protocol being registered before review commencement (11 out of 25) and assessment of present and
likely impact of publication bias (eight out of 25). The breakdown of the AMSTAR 2 assessment for
each study is presented in Supplementary Table S3.
3.2. Association Between Frailty and All-Cause Mortality
A tal of 24 meta-analyses reported the ssociation between frailty and the risk of all-cause
mortality. All 24 studies found that frailty was associated with increased risk of all-cause death.
The reported HR/RRs of the effect of frailty on all-cause mortality ranged from 1.35 to 7.95. The lowest
Geriatrics 2020, 5, 17 8 of 14
HR/RR was reported among diabetes patients and the highest among hospitalized patients. The median
HR/RR estimate of frailty on all-cause mortality across the included studies was 1.98 (IQR 1.65–2.67).
Figure 2 displays a forest plot of the of the reported HR/RR of the association between frailty and
all-cause mortality in the included studies. None of the studies reported age- or sex-specific pooled data.
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Figure 2. Forest plot showing the reported HR/RR of the association between frailty and all-cause 
mortality across the included meta-analyses. HF = heart failure; ACS = acute coronary syndrome; PCI 
= percutaneous coronary intervention; TAVI = TAVI = transcatheter aortic valve implantation 
patients; TAVR = transcatheter aortic valve replacement, LVAD = left ventricular assist device 
implantation; ICU = intensive care unit. 
  
Figure 2. Forest plot showing the reported HR/RR of the association between frailty and all-cause
mortality across the included meta-analyses. HF = heart failure; ACS = acute coronary syndrome; PCI =
percutaneous coronary intervention; TAVI = TAVI = transcatheter aortic valve implantation patients;
TAVR = transcatheter aortic valve replacement, LVAD = left ventricular assist device implantation;
ICU = intensive care unit.
3.3. Association between Pre-Frailty and All-Cause Mortality
All seven meta-analyses that reported the association between pre-frailty and all-cause mortality
found that pre-frailty was associated with increased risk of all-cause mortality. The reported HR/RRs of
the effect of pre-frailty on all-cause mortality ranged from 1.09 among diabetes patients to 3.65 among
hospitalized patients. The median HR/RR estimate of frailty on all-cause mortality across the included
studies was 1.51 (IQR 1.38–1.73). Figure 3 displays a forest plot of the association between pre-frailty
and all-cause mortality in the included studies. None of the studies reported age- or sex-specific
pooled data.
Geriatrics 2020, 5, 17 9 of 14
Geriatrics 2020, 5, x 2 of 21 
3.3. Association Between Pre-Frailty and All-Cause Mortality 
All seven meta-analyses that reported the association between pre-frailty and all-cause mortality 
found that pre-frailty was associated with increased risk of all-cause mortality. The reported HR/RRs 
of the effect of pre-frailty on all-cause mortality ranged from 1.09 among diabetes patients to 3.65 
among hospitalized patients. The median HR/RR estimate of frailty on all-cause mortality across the 
included studies was 1.51 (IQR 1.38–1.73). Figure 3 displays a forest plot of the association between 
pre-frailty and all-cause mortality in the included studies. None of the studies reported age- or sex-
specific pooled data. 
 
Figure 3. Forest plot showing the reported HR/RR of the association between pre-frailty and all-cause 
mortality across the included meta-analyses. ACS = acute coronary syndrome; HF = heart failure. 
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4. Discussion
Increasingly, frailty has been reco ize as a ar er of oor ageing [58], and this syndrome
is associated with many negative health outco es [9–12,15]. However, the a se ce of a lac of a
universally accepted definition creates clinical and research conundrum [59,60]. Moreover, while
frailty is expressed over a broad spectrum of severity, defining the point at which frailty begins is
challenging [1]. An equally important issue also relates to identification of the tip ing point at which
the progression of frailty begins to exert negative effects on survival [20].
With the above in mind, this overview of systematic reviews and meta-analyses provides a
synthesis of the current available evidence of the association between frailty and the risk of all-cause
mortality. We found consistent data across different populations and settings suggesting that both
frailty and pre-frailty are associated with increased risk of all-cause mortality. Across the included
studies, frailty was on average associated with a two-fold increased risk of death, although the risk of
mortality associated with pre-frailty appeared to be much lower.
Although all the included studies suggested frailty and pre-frailty to be associated with increased
risk of all-cause mortality, there was significant heterogeneity in the effect sizes. For example,
while one study reported frailty to be associated with about two times increased risk of death in
community-dwelling adults [42], another study reported frailty to be associated with a nearly eight-fold
increase in risk of mortality among patients hospitalized for a range of conditions [56]. These data
suggest that the mortality effect of frailty across different populations may be graded and could also be
related to other underlying pathological risk factors/stressors that exacerbate the impact of frailty to
varied extents in different populations [21,22].
As frailty is associated with increased risk of mortality, screening for frailty may be useful for
all older adults. However, frailty screening remains a highly debated issue especially in relation to
screening eligibility, as well as where and when it should be performed [3,61]. Regardless, within
specialized geriatric ambulatory care settings and long-term care facilities, the use of comprehensive
geriatric assessments that incorporate the deficit accumulation definition of frailty may be more feasible
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to screen for frailty [62,63], whereas the frailty phenotype may be easier adopt within primary care
settings to identify frail individuals [20].
Healthcare providers need to recognize frailty both as an important baseline condition and an
outcome among older adults. To this end, improved understanding of the risk factors of frailty
is important. Several factors are associated with increased risk of frailty including individual
chronic morbidities such as diabetes, cancers, or depression or their co-existence [3,64,65]. Psychosocial
(e.g., social isolation) and lifestyle factors also play important roles in the development of frailty [3,66,67].
Regardless, studies also suggest that both frailty and pre-frailty can be reversed [68,69]. Thus,
to minimize the risk of frailty development, delay its progression or promote reversal, multidisciplinary
interventions that aim to improve physical, cognitive, and social functioning are required [20,70–72].
In the context of primary care settings, relative effectiveness and ease of implementation of programs
at preventing or slowing frailty progression, ranked from highest to lowest, are strength training,
protein supplementation, comprehensive geriatric assessments, home visits and behavioral change
interventions [72].
Although the present overview provides important insights, some limitations should be considered.
First, the criteria for ascertaining death varied across the primary studies of the meta-analyses,
and therefore misclassification may have affected the estimates of the association between frailty
and the risk of mortality. Secondly, some primary studies may have been included in more than
one meta-analysis and thus the influence of these studies would have been inflated. Thirdly, some
meta-analyses involved primary studies that showed substantial heterogeneity, which may limit the
validity of their, and hence our, conclusions. Furthermore, although the prevalence of frailty and its
mortality effects could vary by age, sex or other characteristics [73–75], we could not examine this
in detail due to limited data. We could also not examine the presence of publication bias due to the
design of our study and the methodology used. Moreover, some meta-analyses were based on small
number of studies showed large effect sizes, which may be suggestive of publication bias in reviews.
Lastly, further bias may have arisen from our limitation of component studies to English, although the
extent of this bias, if present, would likely have been small.
5. Conclusions
Across different populations and settings, frailty defined using multiple criteria is associated with
two-fold increased risk of all-cause mortality. Thus, public health interventions to prevent or slow the
progression of frailty may prevent avoidable deaths.
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